Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07082530

A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China

The investigators are committed to identifying the optimal timing of delivery for low-risk pregnancies. While current guidelines typically recommend induction at 41 weeks, emerging evidence suggests that elective induction at 39 weeks may lead to improved maternal and neonatal outcomes. The U.S.-based ARRIVE trial demonstrated that induction at 39 weeks significantly reduced cesarean delivery rates compared to expectant management, and a similar randomized controlled trial (French-ARRIVE) is ongoing in France. However, population-specific evidence for the Chinese population remains lacking.

This study is designed to establish a prospective cohort of low-risk pregnant women in China, comparing the effects of induction at 39 weeks, induction at 41 weeks, and expectant management on cesarean section rates and other maternal and neonatal outcomes. In addition, multi-omics technologies will be employed to analyze cord blood samples-including metabolomics and proteomics-to identify early biomarkers potentially associated with long-term child health. The study will begin with a pilot phase to assess feasibility and inform operational strategies for large-scale implementation.

The ultimate goal of this project is to generate evidence tailored to the Chinese population to support more individualized decision-making, improve clinical outcomes, and enhance maternal and neonatal safety.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Women's Hospital School of Medicine Zhejiang University

Hangzhou, Zhejiang, 310006, China

Location status: Recruiting

Location contact

Dan Zhang, Ph. D.

PRINCIPAL_INVESTIGATOR

Huajing Gao, MD Candidate

CONTACT

[email protected]

86+18867114750

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years.
  • Singleton pregnancy or twin pregnancy reduced to singleton before 14 weeks.
  • Gestational age between 38 weeks 4 days or 38 weeks 6 days at randomization.
  • Eligible for vaginal delivery with a desire for vaginal birth.
  • Reliable gestational age determination.
  • Maternal and fetal conditions assessed as low-risk by at least two senior obstetricians, with no indications requiring delivery before 41 weeks.
  • Ability to understand study information and provide informed consent.

Exclusion criteria

  • First-trimester ultrasound estimate >13 weeks 6 days.
  • Planned induction before 41 weeks.
  • Planned cesarean delivery or contraindications to vaginal delivery.
  • Already delivered, in labor, or ruptured membranes at enrollment.
  • Placenta previa, vasa previa, placenta accreta, or placental abruption.
  • Contraindications to induction (e.g., cervical cancer, history of uterine rupture, genital tract malformations, abnormal fetal position, cord prolapse).
  • Active vaginal bleeding exceeding spotting.
  • History of cesarean delivery or uterine/cervical surgery.
  • Cervical cerclage during this pregnancy.
  • Maternal conditions not suitable for expectant management beyond 39 weeks (e.g., pregestational diabetes, gestational diabetes requiring insulin, hypertensive disorders, intrahepatic cholestasis of pregnancy).
  • Fetal conditions not suitable for expectant management beyond 39 weeks (e.g., fetal death, major anomalies, growth restriction, macrosomia, anemia, oligohydramnios, polyhydramnios).
  • Maternal infections or positive screenings for sexually transmitted pathogens or group B Streptococcus.
  • Planned delivery at a non-study facility.
  • Participation in another intervention study affecting delivery management.

Treatment and study plan

Labor Induction at 39 Weeks

Procedure

Labor induction at 39 weeks 0 days to 39 weeks 4 days

Expectant management

Procedure

Expectant management until spontaneous labor or induction at 41 weeks.

Primary outcomes

  1. Incidence of cesarean section

    Time frame: Delivery day

    The proportion of deliveries completed by cesarean section

Secondary outcomes

  1. Composite incidence of severe neonatal morbidity and perinatal mortality

    Time frame: Hospital discharge (Day 2-3)

    The composite incidence of any of the following:

    • Antepartum, intrapartum, or neonatal death
    • Intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) for ventilation or cardiorespiratory support within first 72 hours
    • Apgar ≤ 3 at 5 minutes
    • Neonatal encephalopathy
    • Seizures
    • Sepsis (presence of a clinically ill infant in whom systemic infection is suspected with a positive blood, cerebral spinal fluid (CSF), or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection).
    • Pneumonia confirmed by X-ray or positive blood culture.
    • Meconium aspiration syndrome
    • Birth trauma (bone fractures, brachial plexus palsy, other neurologic injury, retinal hemorrhage, facial nerve injury)
    • Intracranial hemorrhage or subgaleal hemorrhage
    • Hypotension requiring pressor support
  2. Emergency Cesarean Rate

    Time frame: Delivery day

    Cesarean delivery performed immediately or shortly after clinical decision due to imminent threat to the life of the mother or fetus

  3. Category 1 Emergency Cesarean Rate

    Time frame: Delivery day

    Cesarean performed within approximately 30 minutes due to immediate life-threatening conditions (e.g., uterine rupture, severe fetal distress)

  4. Category 2 Emergency Cesarean Rate

    Time frame: Delivery day

    Cesarean performed within 60-75 minutes due to urgent but not immediately life-threatening indications (e.g., progressive fetal distress, labor arrest)

  5. Elective Cesarean Rate

    Time frame: Delivery day

    Planned cesarean performed at or after 39 weeks in the absence of emergency conditions, meeting all of the following:

    • Surgery scheduled ≥24 hours before onset of labor;
    • No spontaneous contractions or rupture of membranes;
    • Clear medical indications (e.g., placenta previa, breech presentation) or maternal request.
  6. Operative Vaginal Delivery

    Time frame: Delivery day

    The rate of vaginal deliveries assisted with instruments such as forceps or vacuum.

  7. Gestational Age at Delivery

    Time frame: Delivery day

    Expressed in weeks and decimal days (e.g., 39 weeks + 5 days = 39.7 weeks)

  8. Chorioamnionitis

    Time frame: Delivery day

    Incidence of chorioamnionitis, defined as a clinical diagnosis before delivery as: maternal body temperature rises (>38°C) with 2 or more of the following symptoms:

    • Maternal tachycardia (>100 beats/min);
    • Fetal tachycardia (>160 beats/min)
    • Uterine tenderness and irritability
    • Purulent or malodorous amniotic fluid or vaginal discharge
    • Maternal leukocytosis (white blood cell count > 15000/mm3)
  9. Third-or fourth-degree perineal laceration

    Time frame: Delivery day

    The incidence of third-or fourth-degree perineal laceration

  10. Postpartum hemorrhage

    Time frame: Hospital discharge (Day 2-3)

    Refer to the ARRIVE cohort, defined as any of the following situations:

    • Transfusion
    • Non-elective hysterectomy
    • Use of two or more uterotonics other than oxytocin
    • Other surgical interventions such as uterine compression sutures, uterine artery ligation, embolization and hypogastric ligation, balloon tamponade
    • Curettage
  11. Postpartum infection

    Time frame: Hospital discharge (Day 2-3)

    Refer to the ARRIVE cohort, defined as any of the following situations:

    • Clinical diagnosis of endometritis
    • Wound reopened for hematoma, seroma, infection or other reasons
    • Cellulitis requiring antibiotics
    • Pneumonia
    • Pyelonephritis
    • Bacteremia unknown source
    • Septic pelvic thrombosis
  12. ICU admission

    Time frame: Hospital discharge (Day 2-3)

    The proportion of admission to the ICU

  13. Maternal death

    Time frame: Hospital discharge (Day 2-3)

    The incidence of maternal death

  14. Preeclampsia/gestational hypertension

    Time frame: Hospital discharge (Day 2-3)

    The incidence of preeclampsia or gestational hypertension diagnosed during labor

  15. Maternal venous thromboembolism

    Time frame: Hospital discharge (Day 2-3)

    Deep vein thrombosis or pulmonary embolism

  16. Maternal pain

    Time frame: Hospital discharge (Day 2-3)

    Median patient-reported pain outcomes with a 10-point Likert scale

  17. Birth weight

    Time frame: Delivery day

    The mean birth weight

  18. Female gender

    Time frame: Delivery day

    The proportion of female offspring in terms of physiological gender

  19. Macrosomia

    Time frame: Delivery day

    Birth weight > 4000g

  20. Incidence of large for gestational age

    Time frame: Delivery day

    According to the infant's gender and gestational age, the birth weight exceeds the 90th percentile of infants of the same gestational age

  21. Incidence of small for gestational age

    Time frame: Delivery day

    According to the infant's gender and gestational age, the birth weight is less than the 10th percentile of infants of the same gestational age

  22. Apgar scores at 5 min

    Time frame: Delivery day

    Apgar score at 5 minutes after birth

  23. Neonatal acidosis

    Time frame: Delivery day

    The incidence of neonatal acidosis defined as umbilical artery blood pH < 7.10

  24. Shoulder dystocia

    Time frame: Delivery day

    The incidence of shoulder dystocia

  25. Hyperbilirubinemia

    Time frame: Hospital discharge (Day 2-3)

    The incidence of hyperbilirubinemia requiring phototherapy or exchange transfusion

  26. Transfusion of blood products or blood

    Time frame: Hospital discharge (Day 2-3)

    The incidence of neonatal transfusion of blood products or blood

  27. Hypoglycemia incidence

    Time frame: Hospital discharge (Day 2-3)

    The incidence of hypoglycemia (blood glucose < 35mg/L) requiring intravenous treatment

  28. Neonatal intensive care unit (NICU) admission

    Time frame: Hospital discharge (Day 2-3)

    The incidence of admission to the NICU lasting more than 48 hours

  29. Physical measurement indicators

    Time frame: 6 weeks and 6 months

    Infant weight, length, head circumference, chest circumference, sitting height, upper arm circumference, subcutaneous fat, height-chest circumference index, crown-rump length/length

  30. Growth balance indicators

    Time frame: 6 weeks and 6 months

    Weight-for-length, length-for-age, weight-for-age z scores of infants, calculated using the World Health Organization (WHO) tool, WHO Anthro Survey Analyser

  31. Growth retardation

    Time frame: 6 weeks and 6 months

    Height standard deviation for age < mean-2S or percentile method < P3

  32. Abnormal neurological examination

    Time frame: 6 weeks and 6 months

    The proportion of abnormal results in neurological examinations (hearing development, nerve reflexes)

  33. Scores of Bayley Scales of Infant and Toddler Development (Bayley-4)

    Time frame: 6 weeks and 6 months

    Total score, cognitive scale score, language scale score, motor scale score, social-emotional scale score, adaptive behavior scale score

  34. Scores of Ages & Stages Questionnaires®, Third Edition (ASQ-3)

    Time frame: 6 weeks and 6 months

    Total score, communication domain score, gross motor domain score, fine motor domain score, problem-solving domain score, personal-social domain score

  35. Incidence of allergic diseases

    Time frame: 6 weeks and 6 months

    Allergic diseases diagnosed by neonatologists, including cow's milk allergy, allergic rhinitis, eczema/allergic dermatitis, asthma, wheezing and other allergic disorders

  36. Time from randomization to delivery

    Time frame: Delivery day

    Median time from randomization to birth of the fetus, measured in hours

  37. Use of epidural analgesia

    Time frame: Delivery day

    Rate of epidural analgesia use

  38. Maternal length of hospital stays

    Time frame: Hospital discharge (Day 2-3)

    Median maternal hospital stays, measured in hours

  39. Neonatal length of hospital stays

    Time frame: Hospital discharge (Day 2-3)

    Median neonatal hospital stays, measured in hours

  40. Pre-insurance hospitalization cost

    Time frame: Hospital discharge (Day 2-3)

    Total hospitalization cost during delivery, before insurance reimbursement

  41. Out-of-pocket hospitalization cost

    Time frame: Hospital discharge (Day 2-3)

    Out-of-pocket cost incurred during delivery hospitalization

Other outcomes

  1. Gut microbiota development

    Time frame: Meconium, first 48 hours, 7 days, 3 weeks, 6 weeks, 3 months, and 6 months

    Microbiota richness, dominant species, species transferred from mother to child, sub-group functional trajectory changes of the dominant species in offspring, and the transmissibility of species number and function

  2. Fecal metabolomic characteristics

    Time frame: Meconium, first 48 hours, 7 days, 3 weeks, 6 weeks, 3 months, and 6 months

    Non-targeted metabolomic macroscopic differences, core metabolomic differences (including tryptophan, fatty acids), and differences in gut microbiota metabolites

  3. Cord blood metabolomic characteristics

    Time frame: Delivery day

    Assessment of non-targeted metabolomic macroscopic differences and core metabolomic differences (including tryptophan, fatty acids) in cord blood plasma

  4. Cord blood proteomic characteristics

    Time frame: Delivery day

    Analysis of the proteomic characteristics of cord blood whole blood to trace back the health status during the fetal period

Study contacts

Contact information is provided by the study sponsor or research team.

Huajing Gao, MD Candidate

CONTACT

[email protected]

86+18867114750

Sponsors and collaborators

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University

Other

Registry information

Official study title

Labor Induction in Low-risk Women at 39 Weeks of Gestation: A Randomized Trial in China

Acronym: LIRIC

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jul 24, 2025
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.